You H, et al. - Among patients with pediatric dilated cardiomyopathy (PDCM) (n=94), soluble ST2 (sST2) was assessed for its value in predicting the prognosis. The participants were recruited from 2 centres in China and were followed up for a median of 678 days to determine adverse events (death, cardiac transplantation, and heart-failure–related rehospitalization). Follow-up revealed the occurrence of 28 (29.8%) adverse events. Increased risk of short-term (< 6 months) and long-term adverse events (2 years) was observed in patients in the highest tertile of sST2 levels vs those in lower tertiles. By adding sST2 to B-type natriuretic peptide, an increased C-statistic was generated for short-term and long-term adverse events. Findings revealed the association of serum sST2 levels with adverse events in PDCM cases, as well as robust prognostic value of serum sST2 levels.